Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
12:00 today when spectrum announces viropro at jpm meeting by 2:00 vpro over 16 cents jmho
bashers in full force this morning +.20 cents off we go update for vpro on the way!!!!!
12:00 today Spectrum Pharmaceuticals to Develop Biosimilar Rituximab
* Signs A Binding Letter Of Agreement With Viropro, Inc.
* 2009 Rituximab Sales Were Approximately $5.6 Billion Worldwide
IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has signed a letter of agreement with Viropro, Inc., for the development of a biosimilar version of the monoclonal antibody drug rituximab (marketed by Genentech/Roche). Worldwide sales of rituximab in 2009 in all indications, including non-Hodgkin's lymphoma and chronic lymphocytic lymphoma, were approximately $5.6 billion.
"We are excited at the opportunity to develop our own proprietary biosimilar formulation of rituximab in anticipation of patent expirations for rituximab over the coming years," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc.
Biosimilars, or follow-on biologics, are terms used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity and micro-heterogeneity. Biologics are also very sensitive to manufacturing process changes, including the choice of the cell type, production process, purification process and formulation of the biologic into a drug. In view of the complexity and sensitivity of the biologics to manufacturing process, no two biotech medicines can be exactly the same, hence the term "biosimilar." A number of biosimilar products are already in the market in Europe. Following enactment of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), an abbreviated approval pathway for biosimilars has been created in United States.
oh i took a bunch myself
oh sorry bud,maybe possible ..i am actually glad he's gone,just seems way overpaid
what is good however is that we will get a new investor relations person.and a brand new pr machine..cha ching$$$$$$$$$
has nothing to do with spectrum it's in an employment contract upon termination he must sell his shares that simple no big deal
he may need to before his resignation
buzzie you pull master "bull crap" bait/switch change id's..trying to convince people to sell here is "moot" mark my word..i'll see you at a buck or more!!!!!!
the world is just getting news of vpro and a windfall of investors will learn the power of technology we own$$$$$$$$
europe news just out 4 hours ago MADRID, 12 Ene. (EUROPE PRESS) -
Sandoz has announced the beginning of a clinical test of phase II in patients with biosimilar of rituximab (“Rituxan” and “Mabthera” of Roche), an indicated monoclonal antibody for affections that include linfoma nonHodgkin and reumatoide arthritis.
During the past few years, Sandoz has developed a process for the production of biosimilar of rituximab in its facilities of Schaftenau (Austria). In order to guarantee the biosimilitud with the reference product, a physico-chemical and functional analysis of the product with the later use of bioanalíticas techniques and other studies was carried out “exhaustive”.
The data suggest biosimilar Sandoz of rituximab has a high degree of similarity with the reference product, which justifies the beginning of clinical studies with patients.
According to the company, this study in patients with reumatoide arthritis “tries to demonstrate the bioequivalencia with the reference product and will pick up data on the pharmacokinetics and farmacodinamia as well as data of effectiveness and security”.
The monoclonal antibodies are therapeutic products based on proteins, produced by means of lines cellular and obtained by genetic engeneering. Oncology and the autoimmune diseases work like treatments directed that offer a therapeutic hope in many fields with needs nonsatisfied, particularly in complex therapeutic scopes like.
this in Chinese http://www.bioon.com/industry/drug/471141.shtml
ok guys i just translated this (4 hours old} Spectrum and Viropro will study the development of [biodzhenerika]
Spectrum Of pharmaceuticals and Viropro Of inc will study the development of [biodzhenerika] of the known antitumorigenic preparation Of rituximab, joint production Of roche/Genentech, reports “[KhimRar]”.
At present, Rituximab is intended for the protein CD20 and is approved as the treatment of chronic lymphocytic leukemia, [nekhodzhkinskoy] lymphoma ([NKHL]), and rheumatic arthritis. Preparation assembled 5.6 billion dollars in international sales during 2009 g. the patent protection, which covers its different use, as they expect, since October 2014. it will begin to conclude.
During the treatment [NKHL] Of rituximab is used as the first line, the second line and the supporting therapy. Preparation is sold Roche in Europe under the commercial stamp Of mabThera, and in the remaining part of the peace - as Rituxan of Biogen Of idec and Genentech, with exception of Japan, where the preparation is together sold by the companies Of chugai and Zenyaku Of kogyo.
The bill of the reform of public health, accepted in the past year by President [Barak] [Obamoy], included the legislation, which ensures the way of the approval of biosimilars. According to law about the price competition and the innovations of biological medicines (Biologics Of price Of competition and Innovation of Acts) original biological preparations and control preparations, will possess the 12-year period of [eksklyuzivnosti].
During this time, FDA will not in the state sanction biosimilars through the accelerated mechanism, by which the aspirants can pass all or specific clinical tests. However, companies, which conduct the complete set of clinical tests, can obtain approval FDA by completely legal way, it is analagous to how this occurs for the biological preparations and not to wait 12 years. Bio-like claims cannot be given to the expiration of four year old period after the approval of standard product.
As report the analysts of industry, in the world, between 2008 and 2015 yr., biologicals 59 billion of dollars confronting, they will lose patent protection. In contrast to the [nepatentovannykh] means, which, after appearing on the market, lead to the 90% price erosions of [brendovykh] preparations (after the loss by the latter of patent protection), brought out for the market for biosimilars they can cost only to 30-50% less than biologicals. It is expected that since 2012 ; the market for biosimilars will show an increase in the incomes of by approximately 10 billion dollars each year - and so it will continue, as a minimum, until 2020.
News of medicine and pharmacy from [Remedium]
The keywords: Spectrum, Viropro, development, [biodzhenerik]
Last [videonovosti]
thanks mr bill for trying to help unfortunately i am stuck with this pig and crappy management team
fool me once ain't gonna fool me again
halted?
EMAILWIRE.COM, January 12, 2011 ) Minneapolis, MN - Viropro Inc. (Other OTC:VPRO.PK) has recently became the "it" stock. (VPRO) has the volume and momentum needed to propel (VPRO) to the next level. Make sure to add (VPRO) to your watch lists.
class action lawsuit please let me know im in as well as others i know
no mr bill ceo got 450 million shares pre r/s 30 mil post
pennytrader might just be timothy sykes caught with a squeezzee lol
was it 10-1 r/s ? 30 million 30x's 10=300 million sorry math was off still that was the entire o/s count
see if i can short it
oh and i stated to the company i will sell this is bull$hit!!!tomorrow is a snow day so office will again be closed.this company is a joke playing games, i for one am not!!!!and nobody will play games on my dime..they were warned.i am serious and very pissed i am also considering a class action lawsuit!!!!
oh yes sorry 30 million what would be 3 billion pre split i believe
why ceo gets 3 billion shares?he lost 100% of shareholders equity and he get 3 million shares ..what is that 3 billion pre reverse split?i tried to call the company and i have left messages no avail so i will kill the stock at a loss i don't give a flying #$%^!!!!
i am going to kill this stock
new ir director and big news on the way i see alot of pr's in the future i would be very afraid if i were short on vpro this is running on jet fuel
LOAD THE BOAT MASSIVE SHORT COVER HERE
is a pharmaceutical company. The company is engaged in the business of marketing technological transfers. The company is operational in South America, Asia and North Africa. The company has various strategic alliances. The company is based out of Canada. The company has announced that it has entered into a definitive agreement with Spectrum Pharmaceuticals. The agreement is with regards to the development of a Rituximab biosimilar. The company also said that it has accepted the resignation of Mr. Serge Beausoleil from the board member position.
This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell any stock mentioned in this report at any time after this post.
"Viropro, a biotech drug maker, said Spectrum will license the rights to certain technology and it should get milestone payments over 36 months and royalty payments from ensuing sales." this is what i am digging on i have been trying to contact sppi ir for some insight here
Spectrum Pharmaceuticals Inc. (SPPI) signed a deal with Viropro Inc. (VPRO) to develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's (RHHBY, ROG.VX) cancer drug rituximab ahead of its U.S. patent expiration in 2015.
The agreement comes as many patent expirations loom over large pharmaceutical companies. Rituximab, used in the treatment of many lymphomas, leukemias, transplant rejection and some autoimmune disorders, saw worldwide sales of about $5.6 billion in 2009.
Financial terms weren't disclosed.
Viropro, a biotech drug maker, said Spectrum will license the rights to certain technology and it should get milestone payments over 36 months and royalty payments from ensuing sales.
Biosimilar drugs are officially approved versions of biopharmaceutical products made by a different company as patent and exclusivity expire on the product.
Biotech company Spectrum, which has a focus on cancer treatment, has been focused on making another push to improve the weak sales of its leading drug Zevalin. In its most recent quarterly results, Spectrum swung to a loss as it spent more to market Zevalin and another drug, Fusilev, which treats a vitamin deficiency in patients who have been treated with chemotherapy for colorectal cancer.
Meanwhile, Roche, the world's biggest maker of cancer drugs, is facing pressure following the U.S. Food and Drug Administration December decision to revoke approval of blockbuster drug Avastin for the treatment of breast cancer. The company has said it will appeal.
Spectrum shares were up 4 cents at $6.92. The stock is up 49% over 12 months.
i really don't care what anyone on this board posts i trade for my personal investment if i go broke ..fine, i am willing to take that chance..but if you want my shares you will pay me alot for them.as i average down and continue to buy more.these people will come and go i'll be here 3 months from now sitting on easy street counting thousands$$$$$$
and ill buy all they got
risk/rewards benefit the buyers at this price
i buy when people sell ..that's what good traders do!!!!!
this is a buy out target at this price
hey guys read this http://www.linkedin.com/pub/rajiv-datar/4/5b2/89b
funny thing is that news can hit any given moment and send this stock soaring..and if during market hours massive covering will take place real fast buying and you won't catch this
look at this news i just found and i think sppi will fast track this drug and viropro will be at work quick to get this drug developed....http://www.foxnews.com/health/2011/01/10/novartis-moves-ahead-drug-treat-non-hodgkins-lymphoma/
im all in i bought big here i am going to go long on this stock i think we will get a near term run as well with pending update this week..i will hold this stock tight,i think the sppi news is great and this stock is extremely undervalued at this price.do whatever you want as i really don't care the stock will correct itself to fair value that i believe is over 1.00 in the next few months..thanx again for you shares and support